(ACT) AlzChem - Overview
Stock: Specialty Chemicals, Guanidine Salts, Ceramics, Agriculture, Renewable Energy
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.42% |
| Yield on Cost 5y | 9.12% |
| Yield CAGR 5y | 23.65% |
| Payout Consistency | 95.2% |
| Payout Ratio | 58.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 45.2% |
| Relative Tail Risk | -9.69% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.78 |
| Alpha | 125.98 |
| Character TTM | |
|---|---|
| Beta | -0.102 |
| Beta Downside | -0.043 |
| Drawdowns 3y | |
|---|---|
| Max DD | 24.13% |
| CAGR/Max DD | 4.26 |
Description: ACT AlzChem January 16, 2026
AlzChem Group AG (XETRA: ACT) is a German-based chemical producer operating through three divisions: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The company sells a broad portfolio of specialty chemicals, raw material intermediates, and infrastructure services across Europe, Asia, and North America, serving end-markets such as food, animal feed, defense, renewable energy, and pharmaceuticals.
In 2023 the group generated roughly €1.2 billion of revenue with an adjusted EBITDA margin near 12 % (source: FY-2023 report), reflecting solid pricing power in high-value niches like silicon-nitride ceramics and guanidine-based agro-chemicals. Key economic drivers include the rising demand for silicon nitride in electric-vehicle power electronics, volatile lime and electricity costs that affect the Basics & Intermediates segment, and the ongoing expansion of renewable-energy projects that boost sales of photovoltaic-related adhesives and DYHARD-brand products. The company’s capex plan of about €100 million for 2024 is aimed at expanding its chemical park capacity and upgrading energy-intensive processes.
Given AlzChem’s diversified product mix and exposure to growth sectors, a quick look at its valuation multiples on the ValueRay platform can help you gauge whether the current market price reflects these fundamentals.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 61.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -14.46 > 1.0 |
| NWC/Revenue: 35.93% < 20% (prev 27.07%; Δ 8.86% < -1%) |
| CFO/TA 0.19 > 3% & CFO 112.6m > Net Income 61.8m |
| Net Debt (-79.6m) to EBITDA (110.0m): -0.72 < 3 |
| Current Ratio: 2.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (10.1m) vs 12m ago -0.72% < -2% |
| Gross Margin: 55.07% > 18% (prev 0.39%; Δ 5468 % > 0.5%) |
| Asset Turnover: 105.1% > 50% (prev 116.7%; Δ -11.60% > 0%) |
| Interest Coverage Ratio: 16.46 > 6 (EBITDA TTM 110.0m / Interest Expense TTM 5.24m) |
Altman Z'' 4.98
| A: 0.34 (Total Current Assets 310.1m - Total Current Liabilities 108.1m) / Total Assets 589.5m |
| B: 0.32 (Retained Earnings 186.8m / Total Assets 589.5m) |
| C: 0.16 (EBIT TTM 86.2m / Avg Total Assets 534.8m) |
| D: 0.59 (Book Value of Equity 207.0m / Total Liabilities 353.7m) |
| Altman-Z'' Score: 4.98 = AAA |
Beneish M -3.33
| DSRI: 0.97 (Receivables 74.1m/76.0m, Revenue 562.1m/560.4m) |
| GMI: 0.70 (GM 55.07% / 38.80%) |
| AQI: 1.13 (AQ_t 0.07 / AQ_t-1 0.06) |
| SGI: 1.00 (Revenue 562.1m / 560.4m) |
| TATA: -0.09 (NI 61.8m - CFO 112.6m) / TA 589.5m) |
| Beneish M-Score: -3.33 (Cap -4..+1) = AA |
What is the price of ACT shares?
Over the past week, the price has changed by -6.86%, over one month by -7.57%, over three months by +1.55% and over the past year by +128.19%.
Is ACT a buy, sell or hold?
What are the forecasts/targets for the ACT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 176.9 | 22.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 199.2 | 38.3% |
ACT Fundamental Data Overview February 03, 2026
P/E Trailing = 25.9247
P/E Forward = 21.4592
P/S = 2.7961
P/B = 6.804
Revenue TTM = 562.1m EUR
EBIT TTM = 86.2m EUR
EBITDA TTM = 110.0m EUR
Long Term Debt = 41.1m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 9.41m EUR (from shortTermDebt, last fiscal year)
Debt = 52.8m EUR (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -79.6m EUR (from netDebt column, last quarter)
Enterprise Value = 1.58b EUR (1.61b + Debt 52.8m - CCE 79.6m)
Interest Coverage Ratio = 16.46 (Ebit TTM 86.2m / Interest Expense TTM 5.24m)
EV/FCF = 37.66x (Enterprise Value 1.58b / FCF TTM 42.1m)
FCF Yield = 2.66% (FCF TTM 42.1m / Enterprise Value 1.58b)
FCF Margin = 7.48% (FCF TTM 42.1m / Revenue TTM 562.1m)
Net Margin = 11.00% (Net Income TTM 61.8m / Revenue TTM 562.1m)
Gross Margin = 55.07% ((Revenue TTM 562.1m - Cost of Revenue TTM 252.5m) / Revenue TTM)
Gross Margin QoQ = 32.22% (prev 70.85%)
Tobins Q-Ratio = 2.69 (Enterprise Value 1.58b / Total Assets 589.5m)
Interest Expense / Debt = 2.37% (Interest Expense 1.25m / Debt 52.8m)
Taxrate = 27.82% (6.30m / 22.6m)
NOPAT = 62.2m (EBIT 86.2m * (1 - 27.82%))
Current Ratio = 2.87 (Total Current Assets 310.1m / Total Current Liabilities 108.1m)
Debt / Equity = 0.22 (Debt 52.8m / totalStockholderEquity, last quarter 235.7m)
Debt / EBITDA = -0.72 (Net Debt -79.6m / EBITDA 110.0m)
Debt / FCF = -1.89 (Net Debt -79.6m / FCF TTM 42.1m)
Total Stockholder Equity = 219.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.56% (Net Income 61.8m / Total Assets 589.5m)
RoE = 28.12% (Net Income TTM 61.8m / Total Stockholder Equity 219.9m)
RoCE = 33.04% (EBIT 86.2m / Capital Employed (Equity 219.9m + L.T.Debt 41.1m))
RoIC = 24.13% (NOPAT 62.2m / Invested Capital 257.9m)
WACC = 5.42% (E(1.61b)/V(1.66b) * Re(5.54%) + D(52.8m)/V(1.66b) * Rd(2.37%) * (1-Tc(0.28)))
Discount Rate = 5.54% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.36%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈66.7m ; Y1≈43.8m ; Y5≈20.0m
Fair Price DCF = 70.90 (EV 636.7m - Net Debt -79.6m = Equity 716.3m / Shares 10.1m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 87.62 | EPS CAGR: 43.79% | SUE: 2.38 | # QB: 1
Revenue Correlation: 41.34 | Revenue CAGR: 5.81% | SUE: -0.01 | # QB: 0
EPS next Year (2026-12-31): EPS=6.41 | Chg30d=-0.192 | Revisions Net=-3 | Growth EPS=+4.9% | Growth Revenue=+8.0%